Patient Preference

Brett Hauber, PhD

Senior Economist and VP, Health Preference Assessment RTI Health Solutions


Affiliate Associate Professor University of Washington School of Pharmacy



Patient Preference Testing

- Uses established methods to quantify patients' perspectives on benefits and risks
- Expands upon what may be heard from individual patients in an open public hearing
- CDRH issued patient preference testing guidance in 2016
- The study suggests that there is a group of patients in the target population for whom the benefit of a coil treatment likely outweighs the risks when compared to the outcomes of maximum medical therapy

The Patient Benefit-Risk Continuum for Emphysema Interventions



Adapted from Irony T, Ho M. Incorporating Patient Preferences into Regulatory Decision Making. Society for Medical Decision Making. St. Louis, MO 2015.

Patient Preference Study Design

Objective

 Quantify preferences for benefits and risks of emphysema treatments from the patient perspective

Endpoint

 Proportion of patients who perceive that the benefit of endobronchial coils outweighs the risks

Study participants

- Recruited through US clinical centers that treat patients for severe emphysema
- 202 Coil-naïve participants not enrolled in RENEW
- Eligibility criteria similar to RENEW's
- 7 RENEW sites and 1 non-RENEW site

Improving Breathlessness With Activity is the Primary Treatment Goal for Patients With Severe Emphysema

"Everything else is related to shortness of breath."

"If I didn't have shortness of breath, I'd be OK."

"The <u>shortness of breath</u> thing for me is the whole thing."

"If I could get my breath, I could do whatever."

"[breathlessness]
is the manifestation of the disease that most concerns me."

SGRQ Item 11 Measures Breathlessness and was Used as the Measure of Benefit in the Patient Preference Study


Improvement in breathlessness reflects how patients think about the benefits of treatment




SGRQ Item 11
measures patientreported
breathlessness
with activity

Benefit: Improvement in Breathlessness With Activity (SGRQ Item 11)

Baseline



With improvement



Example Survey Question


TX

RISK


	Treatment A	Treatment B
	Implantable lung device	Medicines
Chance of <u>improvement</u> <u>in shortness of breath</u> in the next year		के के के के के के
	40 out of 100 people (40%) have improved shortness of breath	25 out of 100 people (25%) have improved shortness of breath
Difference in <u>flare-ups</u> in the next year	1-2 more flare-ups	No change in flare-ups
Additional risk of collapsed lung in the next year	Small chance (10%)	No chance
Additional risk of pneumonia requiring hospitalization in the next year	15 additional cases in 100 people (15%)	None
Additional risk of dying in the next year	None	None
Which treatment would you choose?	V	

The Study Suggests There is a Group of Patients in the Target Population for Whom the Benefit of a Coil Treatment Likely Outweighs the Risk when Compared to Maximum Medical Therapy





Survey Sample With RV ≥225%



Patient preference for the additional risk of pneumonia requiring hospitalization was extrapolated from 15% to 17.5% (full sample) or 17.3% (RV ≥225% predicted).

Note: Figure was not provided within the PMA; however, underlying information / analysis was included.

Risks > Benefits (68%)